ModDetect™

ModDetect™ reagents (patent pending) enable universal, sequence-independent detection of chemically modified oligonucleotides, supporting a wide range of RNA therapeutic (RNA Tx) modalities and nucleic acid structures. By eliminating the need for sequence-specific probes, ModDetect provides a cost-effective, low-risk analytical solution that can accelerate candidate triage by 9–12 months during drug development.

Browse all ModDetect Products

Phosphorothioate Panels

Reliably detect phosphorothioate (PS) modifications across sequences, enabling clear visualization and quantification in cells and tissues.

2’-O-Methoxyethyl Panels

Provides universal detection of 2′-O-methoxyethyl (2’-MOE) modifications, supporting both in vitro and in vivo analysis without the need for labels.

2’-O-Methyl Panels

Optimized for sensitive, sequence-independent detection of 2′-O-methyl modifications (2'-OMe) to support delivery and biodistribution studies.

2'-Fluoro Panel (Coming soon)

Designed for accurate, sequence-agnostic detection of 2′-fluoro (2'-F) modifications.

Oligonucleotide Analysis

Let our experts run the analysis for you, using ModDetect to deliver reliable, sequence-independent detection of your drug candidates in cells and tissues.

Overcoming Barriers in Oligonucleotide Detection and Analysis

Accurate detection of oligonucleotides (ONTs) is essential for demonstrating delivery, safety, and efficacy at every stage of drug development. However, current analytical tools are often complex, sequence-dependent, and limited in their ability to detect chemically modified ONTs in serum, cells, and tissues. This gap makes it challenging to generate the robust data needed to advance the best candidates.

ModDetect antibody panels provide reliable, sequence-independent detection of ONTs across a wide range of chemical modifications and assay platforms. Unlike conventional methods, ModDetect works independently of nucleic acid composition, structure, or strandedness, offering researchers a flexible and universal approach to ONT detection.

Explore our Poster: Localization and Quantification of Oligonucleotide Therapeutic Drugs with PS, 2'-MOE, and 2'-OMe Panels

A Better Way to Analyze RNA Therapeutics

Classical assays remain the foundation for characterizing antisense oligonucleotide (ASO) efficacy and safety, but they are strongly influenced by length, sequence, and chemical modifications of the target oligonucleotide. Many suffer from a general lack of sensitivity needed for preclinical assays, creating an unmet need for alternatives. ModDetect provides sensitive and versatile tools for visualization, quantification, and detection in immunocytochemistry (ICC), ELISA, immunohistochemistry (IHC), and other standard immunoassays.

Read our Application Guide: Methods for Analysis of Oligonucleotide Drugs

ADME (Absorption, Distribution, Metabolism, Excretion)

Discovery

Pre-Clinical / Clinical / Non-Clinical

Types of Assays

ELISA/ADA &

Immunogenicity Studies

IP/Protein Binding

In Vitro Cell Culture/

Potency Studies

IHC/Biodistribution

IF/Intracellular

Localization

Why ModDetect™

ModDetect Universal Detection

Universal Detection

Reproducible immunoassay detection of modifications independent of sequence and without labels or tags

ModDetect Broad Application

Broad Application

Validated in serum, cells, and tissues, and compatible with ELISA, IF, IHC, and more for use across research and preclinical pipelines

Accelerated Development

Save 9-12 months in drug development with faster candidate triage and simplified preclinical evaluation

How ModDetect Compares

The ModDetect™ platform delivers high sensitivity (~1 pM), fast throughput, and universal detection for ASO quantification. The table below compares ModDetect to LC-MS, hELISA, branched DNA, and qPCR, highlighting its ability to match leading methods in sensitivity while reducing complexity and eliminating the need for sequence-specific probes.

ModDetect comparison to other methods for ASO

Featured ModDetect™ Publications

Bioanalytical Assays for Oligonucleotide Therapeutics: Adding Antibody-based Immunoassays to the Toolbox as an Othogonal Approach to LC-MS/MS and Ligand Binding Assays
Chimento, D.P. et al. Nucleic Acid Therapeutics, 2025.

READ PUBLICATION

Characterizing Antibodies Targeting Antisense Oligonucleotide Phosphorothioate and 2′-O-Methoxyethyl Modifications for Intracellular Trafficking and Biodistribution Studies
Fial, I. et al. Nucleic Acid Therapeutics, 2025.

READ PUBLICATION

Harnessing BET-Bromodomain Assisted Nuclear Import for Targeted Subcellular Localization and Enhanced Efficacy of Antisense Oligonucleotides
Kashyap, et al. Journal of the American Chemical Society, 2025.

READ PUBLICATION

Go Deeper with ModDetect™

Explore the data behind the science. Visit our Resource Hub for protocols, validation data, and peer-reviewed publications demonstrating ModDetect in action.

View ModDetect Resources